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Abstract
Devil facial tumour 1 (DFT1) is a transmissible cancer clone endangering the Tasmanian
devil. The expansion of DFT1 across Tasmania has been documented, but little is known of
its evolutionary history. We analysed genomes of 648 DFT1 tumours collected throughout
the disease range between 2003 and 2018. DFT1 diverged early into five clades, three
spreading widely and two failing to persist. One clade has replaced others at several sites,
and rates of DFT1 coinfection are high. DFT1 gradually accumulates copy number variants
(CNVs), and its telomere lengths are short but constant. Recurrent CNVs reveal genes
under positive selection, sites of genome instability, and repeated loss of a small derived
chromosome. Cultured DFT1 cell lines have increased CNV frequency and undergo highly
reproducible convergent evolution. Overall, DFT1 is a remarkably stable lineage whose
genome illustrates how cancer cells adapt to diverse environments and persist in a parasitic
niche.
Introduction
Devil facial tumour 1 (DFT1) is a transmissible cancer affecting Tasmanian devils (Sarcophilus
harrisii), marsupial carnivores endemic to the Australian island of Tasmania. Spread between
devils by the transfer of living cancer cells through biting, DFT1 usually manifests as tumours
on the head or inside the mouth [1,2]. Animals with symptoms consistent with DFT1 were
first observed in north-east Tasmania in 1996, and the disease has subsequently expanded
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across the island [3,4]. DFT1 is usually fatal and has caused significant declines in devil popula-
tions, posing a serious conservation threat to the species [3–5].
Unlike most cancers, which arise from and remain confined within the bodies of their
hosts, DFT1 is a clonal lineage derived from the somatic cells of an individual “founder devil.”
Rather than dying together with this animal, DFT1 continued to survive by spreading as an
allogeneic graft through the devil population [1]. Tracing the genomic changes in this long-
lived and divergent cell lineage provides an opportunity not only to map the clone’s routes
through the Tasmanian landscape but also to investigate its underlying evolutionary processes.
Cancer evolves via positive selection acting on somatic genetic changes promoting adapta-
tion to the malignant niche. DFT1 cells have encountered particularly diverse environments
during the lineage’s expansion, including those of genetically and immunologically variable
devil hosts, different tissues within the host including internal metastases, and even artificial
conditions such as laboratory cell culture. The exposure of parallel DFT1 sublineages to such
environments creates a natural experiment for observing the evolution of cancer cell adaption.
In addition, competition between genetically distinct DFT1 sublineages for a limited host pop-
ulation may drive evolution of traits influencing disease transmission, and tracking the inter-
actions and changing distributions of DFT1 sublineages within and across populations could
identify clones with competitive advantage. Here, we document the geographical expansion,
genomic alterations, and lineage dynamics of the DFT1 outbreak, providing insight into the
evolution of a cancer turned infectious disease.
Results
DFT1 phylogeny and lineage dynamics
We skim sequenced (approximately 1×) the whole genomes of 648 DFT1 tumours, together
with those of their matched hosts, collected throughout Tasmania between 2003 and 2018 (S1
Table). Single nucleotide variants (SNVs) were called individually on each tumour and then
assessed across the panel of tumours and hosts (Methods). A total of 456 SNVs showing phylo-
genetic signal in tumours and absence in hosts were genotyped using molecular inversion
probes (MIPs; median 378× coverage, S2 Table) and, together with 94 somatic mitochondrial
mutations and 932 copy number variants (CNVs; S2 and S3 Tables), used to construct a DFT1
phylogenetic tree (Fig 1A and S1 Fig).
The DFT1 phylogenetic tree reveals a series of early (pre-2003) nodes, which define five
tumour groups, named clades A to E. Two clades, D and E, contain only two and one tumours,
respectively, and appear to represent divergent DFT1 sublineages which have not persisted
(Fig 1A and S1 Fig). Clades A, B, and C, which together represent 99% of tumours in the sam-
ple, are each broadly distributed across Tasmania and show distinctive geographical and tem-
poral patterns (Fig 1B and 1C and S2 Fig).
The distribution of DFT1 clades supports epidemiological evidence suggesting that DFT1
originated in the 1980s or 1990s in north-east Tasmania and first spread rapidly into high-den-
sity devil populations in central and eastern areas before a gradual movement towards the
more isolated north-west [3,4]. Tumour sublineages that diverged early within all three major
clades (A, B, and C) are detectable in the north-east, suggesting that the three clades’ most
recent common ancestor may have been located there (Fig 1A and 1B and S1 Fig). After diver-
gence from this common ancestor, clade A split into two sublineages, clades A1 and A2, the
former spreading south along the east coast and becoming apparently confined to three south-
facing peninsulas and the latter colonising central Tasmania and entering naïve host popula-
tions at the north-western and southern disease fronts (Fig 1C). Clade B has widespread pres-
ence throughout central, northern, and eastern Tasmania, and clade C has followed a westerly
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trajectory, spreading out of the north-east and driving DFT1 towards the remote west coast
(Fig 1C). The patterns of connectivity within the devil population revealed by DFT1 lineage
tracing reflect host genetic substructure and may be explained by geographical features [6–8].
The interaction between DFT1 clades over time reveals local patterns as well as large-scale
trends (Fig 1D). In several populations, clade B has increased in prevalence and replaced clade
A (Fig 1D). Sequential lineage replacements have occurred between subgroups of clade A1
(clades A1–3A, A1–3A2, and A1–3A3) isolated on the Forestier Peninsula (Fig 1D), as previ-
ously described [9], and may have been due to DFT1 bottlenecks driven by a conservation
management trial involving regular removal of diseased animals [10].
DFT1 coinfection, which occurs when individual devils carry genetically distinct DFT1 sub-
lineages from separate exposures, has been observed in devils, but its frequency is unknown
[9]. Exactly 100 devils within the cohort hosted two or more sampled DFT1 tumours, and, in
63 of these, the genotypes of these tumours were indistinguishable or could be distinguished
only by variation private to the individual (S4 Table). However, tumours in the remaining 37
devils had distinct genotypes, which were also found in tumours affecting other individuals in
the population (Fig 1E and S4 Table). Most of this latter set likely represent coinfection, but in
some cases, we may have sampled the source of a new genotype. This not only confirms that
carrying one DFT1 tumour does not generally protect devils from subsequent infection but
also implies that opportunities for within-host competition between sublineages may influence
DFT1 evolutionary dynamics [11,12]. To gain insight into the bodily distribution of DFT1
tumours, we superimposed data from 96 DFT1-infected individuals onto a facial map, impli-
cating the lower jaw as the most frequent site of DFT1 tumours (Fig 1F and S3 Fig and S1 Data
in https://doi.org/10.5281/zenodo.4046235). Genotyping also identified relationships between
primary facial and internal metastatic tumours within individual hosts (S4 Table). Overall,
these studies trace the progression of DFT1 over two decades, revealing geographical routes of
expansion through Tasmania, patterns of coinfection and metastasis, and the dynamics and
persistence of parallel DFT1 strains.
Fig 1. DFT1 phylogeny and lineage dynamics. (A) Phylogenetic tree constructed using 550 SNVs and 932 CNVs genotyped across 639 DFT1
tumours (9 tumours were excluded from tree due to missing data). Each tip represents a tumour, coloured by clade. Branch lengths are
proportional to number of variants, not evolutionary time, and high-resolution bootstrapped tree is available in S1 Fig. Tumours sampled in
the north-east of Tasmania (Wukalina), the putative origin of DFT1, are indicated with arrowheads. SNV and CNV genotypes are available in
S2 and S3 Tables, respectively. (B) Map of Tasmania showing distribution of DFT1 clades represented by 593 tumours in (A) and S1 Table
(metastases, tumours involving captive devils, and cases of repeated sampling of individual tumours are excluded (S1 Table)). Each tumour is
represented by a coloured symbol. Mapping coordinates have been randomly offset in heavily sampled labelled locations in order to aid
visualisation. Sample density reflects trapping effort, not tumour prevalence. Tumour clade data and geographical coordinates are available in
S1 Table. Map outline was obtained from https://library.unimelb.edu.au/collections/map_collection/map_collection_outline_maps. (C)
Spatial spread of DFT1 clades. Each tumour is represented by a coloured symbol. Arrows represent putative spatial movements interpreted
from the phylogeny, and year when the DFT1 clade was first observed in each location within the set of sampled tumours is marked. Dotted
lines demarcate inferred distributions of clades A2 and B before sampling for this study began, with arrows illustrating inferred tumour
migrations out of these core areas. Tumour clade data, sampling dates, and geographical coordinates are available in S1 Table. Map outline
was obtained from https://library.unimelb.edu.au/collections/map_collection/map_collection_outline_maps. (D) DFT1 clade distribution in
nine locations indicated on map in (B) between 2003 and 2018. Distribution of three clade A1 subgroups is shown in Forestier. Tumour
population size reflects sampling effort, not disease incidence, and is not comparable between sites. Years with consistent sampling efforts
within sites are marked with black dots. All devils were removed from the Forestier Peninsula in 2012 (arrow). Data are available in S1 Table.
(E) DFT1 coinfection. The number of devils with between two and nine independently sampled DFT1 tumours is shown (277 devils had only
one tumour sampled, not shown on plot). Those devils for which genotypes of all sampled tumours were indistinguishable or could be
distinguished only by variation private to the individual are designated as “single infection.” Individual devils hosting tumours with distinct
genotypes known to occur in other devils in the population are labelled “coinfection,” although in some cases this might represent sampling of
the index tumour within which the new variation arose (S4 Table). An image of a coinfected devil (Devil 165) with tumour genotypes labelled
is shown on the right. Underlying data are available in S4 Table. (F) Facial distribution of DFT1 tumours. Diagram was constructed by
superimposing facial tumour locations of 96 DFT1s. Raw data are available in S1 Data in https://doi.org/10.5281/zenodo.4046235. CNV, copy
number variant; DFT1, devil facial tumour 1; km, kilometre; MRCA, most recent common ancestor; SNV, single nucleotide variant.
https://doi.org/10.1371/journal.pbio.3000926.g001
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DFT1 copy number variation
To study genomic heterogeneity within and between DFT1 clades, CNVs were called across
the DFT1 tumour cohort using read coverage in 100-kilobase (kb) intervals. We identified 742
CNVs within 567 DFT1 biopsies (CNVs unique to cell lines were excluded), including 315
gains (copy number (CN) >2) and 427 losses (CN <2) (Fig 2A and S3 Table). Most CNVs
involved complete gain or loss of a single copy, although some higher amplitude gains, homo-
zygous deletions, and subclonal changes were also observed (Fig 2A and S3 Table). Eight
whole genome duplication events [13] were observed across the DFT1 cohort, with some tetra-
ploid lineages persisting through time and others becoming less frequent (S4 Fig). By searching
for CNVs common to all tumours, we reconstructed the copy number profile of the most
recent common ancestor of the DFT1 cohort, which had a largely unperturbed diploid genome
(Fig 2B).
DFT1 gradually acquires CNVs over time, with slight variation between clades and evidence
for an early burst prior to 2003 (Fig 2C and S5 Fig). Average diploid DFT1 genome size has
remained constant since the emergence of the lineage (S6 Fig). Most DFT1s have a similar
number of CNVs; however, several individual tumours carried particularly high CNV burdens,
suggesting that they may have undergone sporadic genomic crises or acquired defects in path-
ways regulating genomic integrity (Fig 2B bottom panel and S1 and S3 Tables). Internal metas-
tases have similar numbers of CNVs to external facial tumours, suggesting that chromosomal
instability does not license metastatic spread in DFT1, as has been suggested in some human
cancers and model systems (S7 Fig) [14–16]. Some subclonal CNVs were clonal in related
tumours occurring in different individuals, suggesting that we sampled the tumour in which
the CNV arose (S5 Table). Shared subclones, however, were only detected in two cases of
repeated sampling of a single tumour, implying that transmission bottlenecks do not favour
the persistence of subclonal cell populations (S5 Table). Overall, these data support the idea
that DFT1 is a stable cell lineage that largely maintains its genomic integrity [9,17].
We constructed a genome map of DFT1 CNVs by superimposing gains and losses identi-
fied across the tumour population onto devil chromosomes (Fig 2D). This revealed a signifi-
cant level of CNV clustering (Fig 2D and 2E). Indeed, some genomic loci were independently
focally gained or lost 27 times across the DFT1 biopsy cohort (Fig 2D and S3 Table). Some
recurrent CNVs were restricted to individual clades, whereas others were identified across
clades (S8 Fig).
Recurrent CNVs may occur due to selection, genome fragility and other processes leading
to breakpoint clusters, or chromosomal instability. In order to assess selection, we annotated
genes occurring in genomic segments that have been independently gained or lost three or
more times within focal (<50 megabase (Mb)) CNVs (Fig 2D and S6 Table). This screen iden-
tified PDGFRB, a receptor tyrosine kinase (RTK) whose amplification likely confers a prolifer-
ative advantage in DFT1 [18], as a strong candidate for positive selection (Fig 2D and S6
Table). PDGFRB has been independently gained eight times, often at high copy number; inter-
estingly, this has occurred three times in tumours at a single location, the Freycinet Peninsula
(S7 Table). Additional recurrent high amplitude focal amplifications were also observed on
chromosomes 1, 4, and 5, possibly targeting RTK ligand NRG2, anti-apoptosis factor BIRC5,
and DNA-binding protein HMGA2, respectively (Fig 2D and S6 Table). Hemizygous loss of
B2M, a component of major histocompatibility complex class I, was observed in all DFT1s
except for the single ancestral divergent clade E tumour (Fig 2B), presenting the possibility
that this event, which likely confers lower immunogenicity [18,19], may have been favoured in
early DFT1 evolution.
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Fig 2. Copy number variation in DFT1. (A) Distribution of diploid DFT1 CNV states and widths, measured in bp. Subclonal copy number states are labelled 1.5, 2.5,
and 3.5, and represent subclonal states between the two closest integer states. CNVs occurring after a whole genome duplication event are excluded. Gain and loss CNVs
with CN2, loss CNVs with CN>2, and gain CNVs with CN<2 represent back mutations. The CNV detection limit was 500 kb (dotted line). Data are available in S3
Table. (B) Representative DFT1 copy number plots. Each dot represents normalised read coverage within a 100-kb genomic window. Tumour identities are, top to
bottom, 377T1 (clade E), 56T2 (clade C), 228T1 (clade A2), and 209T3 (clade A1). The diploid tumour, 228T1, has lost M5, whose CNVs are visible on chromosomes 2
and 5 (red arrows). A CNV encompassing major histocompatibility complex class I component B2M was acquired in the common ancestor of clades A, B, C, and D
(blue arrows). Copy number plots for all tumours are available in S2 Data in https://doi.org/10.5281/zenodo.4046235. (C) Rate of DFT1 CNV acquisition. Each tumour
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Chromosomal instability is characterised by repeated gain or loss of individual chromo-
somes. The recurrent loss of a cassette of genomic loci involving chromosomes 2, 5, and X, an
event which has occurred 27 times within the DFT1 biopsy cohort, represents the loss of
“marker 5” (M5), a small derived chromosome present in the DFT1 most recent common
ancestor (Fig 2F and S3 and S8 Tables) [13,17]. M5 was previously used to define DFT1 karyo-
typic strains for lineage tracing [13,17], and our finding that this chromosome is frequently
lost suggests that reinterpretation of these data may be required (S1 Table). It seems unlikely
that M5 loss is under positive selection, given that it encodes few genes with confirmed
involvement in cancer (S6 Table), and its loss returns the majority of its sequence to a diploid
state; furthermore, two independent instances of M5 gain were also observed (S8 Table).
Rather, M5 may be particularly unstable compared with other chromosomes, perhaps due to
an inefficient centromere [20–22]. Alternatively, M5 loss may represent a background rate of
chromosome nondisjunction, an event which may be poorly tolerated when involving other
chromosomes. Interestingly, M5 has been lost more frequently, relative to opportunity, in tet-
raploid than in diploid DFT1s, even after correcting for ploidy (Fig 2F and S8 Table). The
chromosome has also been retained more frequently in clade B compared with other clades
(Fig 2F and S8 Table), suggesting that alterations in M5 structure or cell function have pro-
moted this chromosome’s stability within the sublineage.
Some genomic loci are particularly vulnerable to DNA breakage or rearrangement due to
processes such as genomic fragility and nonallelic homologous recombination [23,24]. A num-
ber of candidate DFT1 sites of genomic instability were identified, including a 12.5-Mb locus
on chromosome 5, which was independently gained and lost ten times. A total of 144 genomic
breakpoints (at 100-kb resolution) were reused on two or more occasions within the DFT1
lineage (Fig 2D and 2G and S9 Table), although it should be noted that the fragmented state of
the reference genome may inflate the number of breakpoint hotspots observed (S3 Table).
This contrasted with limited breakpoint reuse in 2,000 neutral simulations (Fig 2G).
Selection and genome instability might also involve common DNA regions in non-DFT1
Tasmanian devil cancers. We investigated this by sequencing genomes from 15 DFT2 tumours
(DFT2 is a second Tasmanian devil transmissible cancer that also causes facial tumours [25])
is represented by a grey dot, and labels mark 1 January of the labelled year. Sets of CNVs cooccuring with the same copy number in the same samples are counted once.
CNVs are called relative to the reference genome. Grey shading represents regression standard error, and upper and lower lines represent prediction intervals. We
corrected for ploidy in tetraploid tumours, and cell lines are excluded. Data are available in S1 Table. (D) DFT1 CNV chromosome map. Grey bars represent
chromosomes with scale on left in Mb. Blue and red bars represent copy number losses and gains, respectively. Each bar is an independent CNV occurrence, and CNVs
shared between tumours via a common ancestor are illustrated once. Each CNV step away from CN2 is illustrated separately. Candidate driver genes within frequently
amplified regions are annotated, and complete lists of genes within CNV intervals are found in S6 Table. CNVs associated with M5 are indicated. HMGA2 is not
annotated in the reference genome, Devil7.1, but is inferred to be present in the labelled interval based on cross-species genome alignment. CNVs occurring exclusively
in DFT1 cell lines are excluded. CNV data are available in S3 Table. (E) DFT1 CNVs are more clustered than expected by chance. Number and length of overlapping
CNVs in observed data and in data derived from 2,000 simulations. CNV data are available in S3 Table. (F) Loss of small derived chromosome M5 in diploid and
tetraploid DFT1s and across DFT1 clades. M5 was acquired in a DFT1 common ancestor and is composed of fragments of chromosomes 2, 5, and X; this chromosome
has been repeatedly lost in the DFT1 lineage (cartoon). The Fisher exact tests compare the observed distribution of M5 losses to those expected by chance, with the latter
calculated assuming equal opportunity for M5 loss across all M5–positive tumours, correcting for change in opportunity caused by tetraploidy. Data are available in S8
Table. (G) Frequency of CNV breakpoint reuse within 567 DFT1 biopsies (cell line breakpoints excluded). Ends of chromosomes, M5 CNVs, and instances of reuse
within individual samples are excluded from count. Simulated data are derived from 2,000 neutral simulations. Data are available in S9 Table. (H) Number of CNVs in
Tasmanian devil cancers of different histotypes. “Lymphoma” includes two unspecified cutaneous round cell tumours (S1 Table). CNVs exclusive to DFT1 cell lines are
excluded. Number of CNVs is relative to the reference genome. Each tumour is plotted as a dot, and each non-DFT data point represents an independent clone except
for the three dots representing tumours 106T1, 106T2, and 106T3, which are separate tumours belonging to a single non-DFT cancer. Data are available in S1 and S3
Tables. (I) Frequency of CNV breakpoint reuse across Tasmanian devil cancers. Number of reused breakpoints between pairs or trios of devil cancer groups are shown,
with colours indicating the number of breakpoints within each category which are also reused within individual devil cancer cohorts. DFT1 cell line CNVs, ends of
chromosomes, M5 CNVs, and reuse within individual samples are excluded from count. Simulated data are derived from 2,000 neutral simulations of datasets of the
same size. Simulated data are coloured for breakpoint reuse within group using the same colour key as used for real data, as shown on the plot. None of the reused
breakpoints were found in the genomes of normal devil tissues, including those of matched hosts (S1 Table). Non-DFT, spontaneously arising non-transmissible devil
cancers that are neither DFT1 nor DFT2. Data are available in S9 Table. bp, base pair; CI, confidence interval; CN, copy number; CNV, copy number variant; CN2, copy
number 2; DFT1, devil facial tumour 1; LogR, ratio of tumour to normal reads, log base 2; Mb, megabase; M5, marker 5.
https://doi.org/10.1371/journal.pbio.3000926.g002
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as well as those of ten other spontaneous non-transmissible devil cancers including seven lym-
phomas and round cell tumours, two anal sac carcinomas, and a single sarcoma (S1 Table).
The carcinomas had more than five times more CNVs than other devil cancers, and each har-
boured high copy number amplicons carrying known cancer genes (PIK3CA and MYCL,
respectively), confirming that CNV mutation burden and cancer gene involvement vary across
devil cancer histotypes (Fig 2H and S6 Table). In total, 119 CNV breakpoints (at 100-kb resolu-
tion) were reused across two or more independent devil cancers (where DFT1 and DFT2 are
each considered independent cancers, and each non-DFT tumour is considered an indepen-
dent cancer), while few were expected by chance (Fig 2I). In some cases, pairs of breakpoints
were reused in the same subsets of samples, leading to CNV recurrence (S9 Fig). Many cross-
cancer reused breakpoints occurred more than once within DFT1 and likely reflect common
genomic unstable sites (Fig 2I and S9 Table).
DFT1 cell culture evolution
Laboratory cell lines can be readily established from DFT1 tumours [13,17]. In order to inves-
tigate how DFT1 cells adapt to cell culture conditions, we sequenced genomes from 24 cell
lines derived from diverse DFT1 tumours across the lineage’s phylogeny (Fig 3A and S1
Table). We observed that DFT1 cell lines have significantly more CNVs than DFT1 primary
tumours (Fig 3B). In fact, 421 of 1,163 (36%) CNVs identified in DFT1 were unique to cell
lines, while cell lines constituted only 6% of samples (S3 Table). Additionally, M5 loss is signifi-
cantly more frequent in cell lines than in tumour tissue biopsies (Fig 3C). Altogether, this sug-
gests that introduction to cell culture may select for genetically unstable DFT1 subclones,
although we cannot exclude the possibility that these observations could result from relaxation
of negative selection in DFT1 cell culture.
We generated a chromosomal map displaying the distribution of genomic gains and losses
in DFT1 cell lines (Fig 3D). Remarkably, this revealed that the majority of DFT1 cell lines have
undergone a series of highly distinctive genomic rearrangements (Fig 3D and S10 Table).
These most prominently include losses involving chromosome 4, returning a region gained to
three copies early in DFT1 evolution (see Fig 2B) back to two copies and gains involving chro-
mosome 5. These changes were also observed in cell lines derived from tetraploid lineages, and
losses and gains of a single copy of regions of chromosomes 4 and 5 were observed in these
cases. In four low-passage cell lines, these changes were subclonal, suggesting ongoing evolu-
tion in vitro. The phylogenetic distribution of these cell lines on the DFT1 tree confirms that
the recurrent alterations do not result from accidental laboratory contamination (Fig 3A). Fur-
thermore, these changes were specific to DFT1, as they were not observed in cultured devil
fibroblasts or in DFT2 cell lines (S2 Data in https://doi.org/10.5281/zenodo.4046235). To
determine whether the cell line–specific genomic changes were compatible with growth within
an animal host, we examined nine tumours derived from sequenced cell lines that had been
experimentally introduced into devils [26]. In all of these cases, the cell line genomic configu-
ration was retained in transplanted tumours (Fig 3E).
We annotated the genes present within genomic regions recurrently gained and lost in
DFT1 cell lines to identify potential underlying drivers. Surprisingly, ERBB2, whose activity is
necessary for DFT1 growth [18,27], lies on the arm of chromosome 4 whose third copy is
repeatedly lost in cell lines (Fig 3D), indicating that the selective advantage of undergoing this
change exceeds the cost of losing a copy of ERBB2. Chromosome 5p, which is repeatedly
gained in cell lines, carries the ribosomal DNA (rDNA) locus [28], raising the possibility that
increased ribosome abundance may offer an advantage to DFT1 cells in vitro (Fig 3D). SNV
allele assignment revealed that the chromosomal copies implicated in the events on
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chromosomes 4 and 5 varied among tumours, indicating that the selective advantage is not
allele specific (S10 Fig and S11 Table). Intriguingly, we identified two DFT1 biopsies, one a
Fig 3. Copy number variation in DFT1 cell lines. (A) DFT1 phylogenetic tree with 43 cell lines (including some duplicates collected at different passages), and tissue
biopsies from devils inoculated with cell lines, indicated. DFT1 clades are labelled. Higher resolution tree is available in S1 Fig, and underlying SNV and CNV data used
to generate tree are available in S2 and S3 Tables, respectively. Sample information, including cell line status, is available in S1 Table. (B) Number of CNVs in DFT1
biopsies and cell lines. Data are available in S1 and S3 Tables. (C) M5 loss events in DFT1 biopsies and cell lines. Cell lines derived from tumour lineages lacking M5 are
excluded. Data are available in S8 Table. (D) Chromosome map illustrating CNVs in DFT1 cell lines. Grey bars represent chromosomes. Blue and red bars represent
copy number losses and gains, respectively, which were observed in DFT1 cell lines but not in DFT1 biopsies. Each bar is an independent CNV occurrence, and CNVs
shared by multiple cell lines via a common ancestor are illustrated once. Each CNV step away from CN2 is illustrated separately, thus a CNV present at CN<1 or>3 is
shown multiple times. The location of ERBB2 is marked, together with a window within which the rDNA occurs (exact coordinates are unknown). Data are available in
S3 Table. (E) Representative genomic copy number plots for a DFT1 biopsy, cell line, and experimental inoculation of the same cell line into a devil. Each dot represents
normalised read coverage within a 100-kb genomic window. Tumour identifiers are labelled in parentheses, all three samples belong to Clade A1-3A3 (S1 Table). Copy
number plots for all tumours are available in S2 Data in https://doi.org/10.5281/zenodo.4046235. CN, copy number; CNV, copy number variant; DFT1, devil facial
tumour 1; M5, marker 5; logR, ratio of tumour to normal reads, log base 2; rDNA, ribosomal DNA; SNV, single nucleotide variant.
https://doi.org/10.1371/journal.pbio.3000926.g003
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lung metastasis, with equivalent losses on chromosome 4 and gains on chromosome 5, sug-
gesting that some DFT1 body sites may mimic cell culture conditions, driving DFT1 adapta-
tion (S11 Fig and S10 Table). Overall, these observations reveal that some cancers respond to
altered environments in a highly reproducible manner, indicating that the pathways to achiev-
ing fitness optima are, in some cases, surprisingly limited.
DFT1 telomeres
DFT1 chromosomes have short telomeres compared with those of normal devil cells, but the
cancer is known to express telomerase reverse transcriptase TERT [29,30] (S12 Fig). To investi-
gate if DFT1 telomere length changes with time, we measured the abundance of telomeric
repeats in DFT1 biopsy genomes using tumour purity as a covariate in a linear regression
model. This assay suggests that DFT1 telomere length has remained unchanged in tumours
sampled between 2003 and 2018 (S12 Fig). These results imply that DFT1 telomeres shortened
either before or soon after DFT1 neoplastic transformation; indeed, critically short telomeres
may have contributed to the chromosomal rearrangements observed in the cancer [17,31].
Subsequently, telomere lengths have remained constant, probably due to the activity of
telomerase.
Discussion
This survey of DFT1 genomic diversity reveals a stable neoplastic cell lineage that has altered
relatively little during its spread through the Tasmanian devil population [9,13,17]. Indeed,
more genetic variation, at least at the level of copy number, is frequently found between dis-
tinct tumours of a cancer within an individual human patient or even within a single human
tumour [15,32–36] than is present in DFT1s sampled from devils hundreds of kilometres and
more than a decade apart. These findings suggest that early in its evolution, at least at the com-
mon ancestor of clades A, B, C, and D, DFT1 acquired a genomic configuration compatible
with growth within a range of environments, including those of genetically and immunologi-
cally variable devil hosts and internal metastatic sites.
Nevertheless, despite exceptional adaptation to its niche, there is some evidence of ongoing
positive selection in DFT1. Repeated focal and high amplitude copy number gains involving
the PDGFRB locus suggest selection for increased cell proliferation [18,37]. Surprisingly, given
evidence for strong selective pressures exerted by the host immune system [38], we did not
identify obvious recurrent genomic changes contributing to immune evasion. Such adapta-
tions may not be copy number driven or may involve poorly assembled or annotated portions
of the reference genome. However, the potential for DFT1 to adapt to novel conditions is clear
from the convergent structural changes observed in DFT1 cell lines. Given the declining den-
sity of devils, particularly in eastern and central Tasmania [4], as well as evidence for high fre-
quency of DFT1 coinfection, there is scope for DFT1 inter-lineage competition. Our
observation that clade B has largely remained behind the disease front and repeatedly replaced
other DFT1 sublineages raises the possibility that this clade may have a selective advantage,
perhaps, for example, favouring transmission in post-disease low-density devil populations,
although we cannot exclude the possibility that these dynamics are stochastic. Additionally,
repeated acquisition of PDGFRB copy number gains in tumours of different clades on the
Freycinet Peninsula, coinciding with steady devil population decline [39], suggests the possi-
bility of an arms race towards more virulent DFT1 forms driven by within-host inter-lineage
competition. These findings contrast with the absence of detectable ongoing positive selection
in the 6,000-year-old canine transmissible venereal tumour [40], perhaps reflecting differences
in age and within-host inter-lineage competitive dynamics between the two cancers.
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Although positive selection continues to mould the DFT1 genome, most genetic alterations
in DFT1 are unlikely to offer an advantage. Indeed, the gradual accumulation of mutations
may, in the long term, reduce the lineage’s robustness, especially given evidence that negative
selection may be inefficient in transmissible cancers [40]. Any potential costs of continued
clonal evolution are, however, unlikely to affect the immediate consequences of DFT1 on its
precarious host population.
DFT1 presents a continued and serious threat to the Tasmanian devil, and predicting the
future impact of the disease remains challenging [5,41–43]. The spatial and temporal dynamics
of DFT1 between 2003 and 2018, described here, reveal not only the trajectories of parallel and
competing DFT1 sublineages but also trace the patterns of movement of the diseased devils
themselves. In combination with findings from ongoing population monitoring studies
[4,38,39,44–46], these data may be useful for epidemiological modelling and prediction of
management intervention benefit. The recent emergence of DFT2 [25,45] further exacerbates
the species’ peril and underlines the importance of conservation efforts.
Overall, we have described the phylogeny, lineage dynamics, geographical spread, and
genome evolution of DFT1, providing important information for future Tasmanian devil con-
servation planning and illustrating how a comparatively simple and stable cancer cell lineage
can colonise diverse niches and devastate a species.
Methods
Ethics statement
Animal procedures and sample collection followed a standard operating procedure that was
approved by the General Manager of the Natural and Cultural Heritage Division in the Tasma-
nian Government Department of Primary Industries, Parks, Water and the Environment
(DPIPWE), in agreement with the DPIPWE Animal Ethics Committee and covered by a Sci-
entific Permit issued by the Tasmanian Government, or were approved under University of
Tasmania Animal Ethics Permits A009215, A0011436, A0013685, A0012513, A0014976,
A0010296, A0013326, and A0016789 with State Scientific Permit TFA 19144. Sample collec-
tion procedures were approved by the University of Cambridge Department of Veterinary
Medicine Ethics and Welfare Committee (CR191).
Sample collection and DNA extraction
Biopsies were collected from wild or captive Tasmanian devils or from animals whose car-
casses were found as roadkill. Tumour and host (ear, liver, spleen, blood, gonad, or subman-
dibular lymph node) tissue biopsies were collected into either RNAlater (Thermo Fisher
Scientific, Waltham, United States of America) or ethanol. Fine needle aspirates were collected
into a 1:1 solution of Buffer AL (Qiagen, Hilden, Germany): PBS were sampled from tumours
that were too small to biopsy. Cell lines were established and cultured as previously described
[13,17,18]. Experiments involving inoculation of devils with DFT1 cell lines have been
described [26]. Genomic DNA was extracted using the Qiagen DNeasy Blood and Tissue Kit
(Qiagen). Samples included in the study, as well as metadata for identifying samples used in
various analyses, are listed in S1 Table. Cell lines used in the study are also known by the fol-
lowing external identifiers: 85T (Half-Pea); 86T, 86T2 (1426); 87T, 87T2, 90T, 90T2, 114T,
363T1, 993T1.1, 993T1.2, 994T1.1, 995T1.1, 995T1.2, 996T1, 996T2 (C5065); 88T, 88T2
(4906); 204T (Ed); 202T2 (RV, TD467); 203T3 (SN, TD500). Groups of samples belonging to
the same parental cell line were sampled at different passages or after inoculation into devil
hosts (details in S1 Table).
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Sequencing
Illumina whole genome sequencing libraries were generated with an average insert size of 450
base pairs (bp) using standard methods according to manufacturer’s instructions, and were
tagged with Sanger index tags for multiplexing. We pooled and sequenced approximately 17
samples per lane on an Illumina HiSeq instrument with version 4 chemistry (Illumina, San
Diego, USA) in high output mode with paired-ends (2 × 125 bp) to achieve a median coverage
of 1× per sample. Reads were aligned to the Devil7.1+MT Tasmanian devil reference genome
(http://www.ensembl.org/Sarcophilus_harrisii/Info/Index) [9] using BWA-MEM (http://bio-
bwa.sourceforge.net/bwa.shtml) version 0.5.9-r16+rugo with options “-l 32 -t 6.” PCR dupli-
cates were flagged using Picard (http://broadinstitute.github.io/picard/).
Note on Tasmanian devil chromosome nomenclature
Two Tasmanian devil chromosome nomenclature systems are in use, which differ in the nam-
ing of the two largest chromosomes [1,17]. In both systems, the two largest chromosomes are
named 1 and 2, but the labels for these chromosomes are swapped with respect to each other.
The Devil7.1+MT reference genome [9], used here, follows the system established by Pearse
and Swift [1].
Variant calling and genotyping
Mitochondrial variant calling and filtering. Mitochondrial DNA was sequenced to a
median depth of 275×. Mitochondrial variant calling and genotyping was performed with
Platypus (version 0.8.1) [47]. First, we called SNVs on each sample individually using default
settings with “—minRead = 3” and “—minPosterior = 0.” We merged variants and ran Platy-
pus a second time across all samples. We then removed any variants with flags “badRead,”
mapping quality (“MQ”), or quality depth (“QD”).
We applied the following post-processing filters to the remaining variants:
• Regions filter: Variants mapping within 500 bp from the start or end of the mitochondrial
contig were excluded.
• Low Variant Allele Fraction (VAF) filter: Variants observed with VAF <0.2 were discarded,
as they were considered to be likely due to low-level cross-contamination.
• Germline filter: Variants appearing in both tumour and matched host were discarded as
likely germline contamination. In tumours without matched hosts, variants that had been
discarded in�1 matched tumour were discarded.
We visually validated remaining variants using Integrated Genomics Viewer (IGV) version
2.3 [48].
Mitochondrial DNA (mtDNA) purity was estimated as the mean VAF of tumour-specific
mtDNA variants (S1 Table).
Mitochondrial haplotype nomenclature. We created an mtDNA haplotype nomencla-
ture. Each name begins with a prefix identifying the clone: The DFT1 clone is denoted as
“DFT1_,” and DFT2 is denoted as “DFT2_.” A hierarchical notation is then used, which fol-
lows the mitochondrial tree topology, alternating between numbers and letters (S1 and S2
Tables).
Nuclear variant calling and filtering. Scaffolds from each chromosome in the reference
genome Devil7.1+MT (http://www.ensembl.org/Sarcophilus_harrisii/Info/Index) were
concatenated to produce chromosome-level coordinates for each chromosome (S12 Table).
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SNV calling and genotyping were performed with Platypus version 0.8.1 [47] with options
“—minRead = 1,” “—minBaseQual = 30,” “—badReadsThreshold = 30,” “—filteredReadsFrac
= .8,” “—badReadsWindow = 15,” “—minPosterior = 0,” and “—minFlank = 0.” For the initial
calling, we used Platypus with the parameters described above to identify SNVs in each DFT1
separately. Variants flagged by Platypus as badReads, MQ, strandBias, Median minimum base
quality for bases around variant (MMLQ) <30, and sequence context (SC) were removed. For
the variant set called in each sample, we applied the following filters:
• Regions filter: We excluded variants mapping within 500 bp of the start or end of a contig
and within 1,000 bp from the start and end of a scaffold. Variants called in scaffolds not
assigned to chromosomes and in mtDNA were also removed.
• Simple repeats filter: Variants called within 5 bp from a simple repeat region as annotated by
Tandem Repeat Finder [49] were removed.
Each tumour’s SNV set was then genotyped in its respective matched host (or a single host,
100H, if matched host was unavailable, S1 Table), and variants identified in host were
excluded. We then merged remaining variants into a single file and genotyped this across all
tumours and normals using Platypus with default settings but retaining the “—minReads = 1”
option. Variants flagged with MQ or badReads were excluded, and we retained those variants
with support (�1 reads) in DFT1s but without support (0 reads) in normal devils.
Preliminary phylogenetic tree inference and MIP probe selection
We generated a custom sequence template that concatenated Devil7.1+MT to only include
sites where variants were observed. The IUPAC ambiguity character (N) was substituted at
sites where there was no read coverage across the variant position in a particular sample. We
combined the sequences of genotyped tumours and the reference to generate a sequence align-
ment for phylogenetic tree inference. We constructed a preliminary maximum likelihood tree
rooted with the reference sequence, using the generalised time reversible (GTR) substitution
model with a gamma model of site heterogeneity with Lewis ascertainment bias correction
implemented in RAxML [50]. Using DFT1 mtDNA haplotypes and the preliminary nuclear
SNV tree, we placed tumours into preliminary phylogenetic groups. The SNV set was further
filtered based on these groups in order to select phylogenetically informative SNVs. A total of
600 SNVs were selected for genotyping using MIPs.
MIP genotyping
We designed custom MIP capture probes with a 120-bp target capture size using MIPgen [51].
The common linker sequence CTTCAGCTTCCCGATATCCGACGGTAGTGT was replaced
with CTTCAGCTTCCCGATCCGCTCTTCCGATCT to enable amplification with Sanger
iPCR indexed primers (96-Plex Molecular Barcoding for the Illumina Genome Analyzer
https://link.springer.com/protocol/10.1007%2F978-1-61779-089-8_20). We selected 600
probes which passed the recommended scoring thresholds (>1.4 using the support vector
regression model and 0.7 using the logistic regression model). The oligos were column synthe-
sised and purified using standard desalting (Integrated DNA Technologies, Coralville, USA).
We first pooled the probes at equimolar concentration. We phosphorylated the pooled MIP
probes using T4 Polynucleotide Kinase (New England Biolabs, Ipswich, USA) with conditions
detailed in Table 1 with incubation at 37˚C for 45 minutes followed by heat inactivation at
65˚C for 20 minutes.
Genomic DNA was diluted to 3 ng/μL, and phosphorylated pooled MIP probes were
diluted in EB buffer (Qiagen) to enable a reaction ratio of MIP probes to genome copies of
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800:1. The hybridisation and circularisation reactions were performed as shown in Table 2
using Ampligase (LGC Biosearch Technologies, Hoddesdon, United Kingdom) and Hemo
Klentaq (New England Biolabs).
DNA was denatured at 98˚C for 3 minutes. Temperature was decreased incrementally (1˚C
per second) to 60˚C, held for 1 hour, and the reaction incubated overnight at 56˚C. To select
for the circularised product, we performed an exonuclease treatment (Exonuclease I and Exo-
nuclease III (New England Biolabs)) with the conditions described in Table 3.
The capture reaction was incubated in the exonuclease mix at 37˚C for 40 minutes followed
by 95˚C for 2 minutes to heat inactivate the exonuclease. We then amplified (Q5 High-Fidelity
2X Master Mix, New England Biolabs) our selected product with the MIP forward primer (50-
AATGATACGGCGACCACCGAGATCTACACATACGAGATCCGTAATCGGGAAGCTG
AA�G-30) together with iPCR indexed primers with the conditions specified in Tables 4 and 5.
Library quality was analysed directly on an Agilent 2100 Bioanalyzer System (Agilent Tech-
nologies, Santa Clara, USA) using the Bioanalyzer DNA 1000 Broad Range chip. Libraries
were pooled (5 μL of each library) and size-selected (>150 bp) using Ampure beads (Beckman
Coulter, Brea, USA) at 0.8×. The purified pooled library was eluted in 22-μl buffer EB (Qiagen)
and assessed using a Bioanalyzer High Sensitivity chip (Agilent Technologies).
We first performed a pilot with 96 samples, sequencing the libraries on a MiSeq (Reagent
Kit v3 600-cycle, Illumina) with 150 bp paired-end reads. We demultiplexed and trimmed
adaptors using bcl2fastq2 v2.20 (https://support.illumina.com/downloads/bcl2fastq-
conversion-software-v2-20.html), allowing for no mismatches (“—barcode-mismatches 0”).
We then aligned the reads using BWA-MEM (http://bio-bwa.sourceforge.net/bwa.shtml) to
Devil7.1+MT. Using a customised script based on Allelecount (https://github.com/cancerit/
alleleCount) with min-base-qual = 30, we identified the total number of reads covering the
Table 2. Conditions for MIP hybridisation and circularisation reactions.
Volume (μL) per reaction
Ampligase 10× buffer 1.3
Phosporylated MIP pool (1:1,000 dilution) 0.484
dNTPs (0.1 mM) 0.08
Hemo Klentaq 0.08
Ampligase (5 U/μl) 0.1
Nuclease-free water 0.01
DNA (30 ng) 10
Total 12
dNTP, deoxynucleoside triphosphate; MIP, molecular inversion probe.
https://doi.org/10.1371/journal.pbio.3000926.t002
Table 1. Conditions for MIP phosphorylation reaction.
Volume (μL)
MIP pool (500 μM total concentration) 20
T4 PNK 10
T4 PNK buffer (10×) 7
ATP (10 mM) 7
Nuclease-free water 63
Total 100
ATP, adenosine triphosphate; MIP, molecular inversion probe; T4 PNK, T4 polynucleotide kinase.
https://doi.org/10.1371/journal.pbio.3000926.t001
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region of the SNV, the number of reads supporting each allele, and the number of reads carry-
ing a 5-bp unique molecular identifier (UMI). We calculated the on-target ratios of each probe
by calculating the number of unique reads that mapped to the correct genomic region as a pro-
portion of the total number of reads that carried either or both the extension and ligation
sequences of each probe. We removed overrepresented probes that were greater than 1.5 log
(10)-fold from the overall median UMI read count across samples and probes, and we removed
probes with no representation. We also removed probes that carried greater than 50% median
off-target ratios across the samples. The MIP probe concentration for rebalancing was calcu-
lated by taking the square root of the median coverage over the median coverage for the individ-
ual MIPs. Remaining probes were rebalanced and pooled using an Echo 550 Liquid Handler
(Labcyte, San Jose, USA). Using the rebalanced MIP probes, we remade and sequenced the new
libraries for the same set of 96 samples. From the analysis, we observed that two probes were
over 10-fold higher than the overall median UMI read count across probes. We halved the vol-
ume of these two probes for the input pool using the same rebalanced concentration. We re-
pooled the remaining MIP probes and genotyped across the samples (S2 Table).
Several tumours were sequenced in duplicate, and in these cases, data were merged from
the two sequencing runs. We assessed the number of reads supporting the reference and vari-
ant alleles at each target site as detailed above (S2 Table). We then genotyped variant presence
or absence as follows:
Calculate the expected number of reads for presence: The expected number of reads support-
ing a variant for a diploid site carrying a heterozygous somatic variant was calculated as fol-
lows:
Expected reads ¼ Total reads� purity� 0:5
Purity was defined as the median VAF�2 for variants that pass a minimum threshold of var-
iant read support. The accuracy of this approach was validated by visualising VAF histograms
for each sample.
Table 3. MIP exonuclease reaction conditions.
Volume (μL) per reaction







Table 4. Conditions for MIP amplification and index incorporation.
Volume (μL) per reaction
Q5 High-Fidelity 2X Master Mix 13
MIP F primer (100 μM) 0.13
Indexed MIP R primer (10 μM) 1.3
MIP capture reaction 12
Total 26.4
MIP, molecular inversion probe; F primer, forward primer; R primer, reverse primer.
https://doi.org/10.1371/journal.pbio.3000926.t004
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Genotyping: Genotyping was then performed as follows:
Expected number of reads�10:
• If the observed number of reads supporting a variant was greater than the contamination
threshold (a value calculated individually for each tumour based on the level of cross-con-
tamination (S2 Table)), the variant was considered present.
• If the number of reads supporting a variant was less than the contamination threshold, but
>2 reads, the variant was assigned an ambiguity code “N.”
• If the number of supporting reads was�2, the variant was considered absent.
Expected number of reads<10 but�5:
• If the number of supporting reads was greater than the contamination threshold, the variant
was considered present.
• If the number of reads supporting the variant was less than the contamination threshold, the
variant was assigned an ambiguity code “N.”
Expected number of reads<5:
• The variant was assigned an ambiguity code “N.”
We excluded variants observed to be present in normal tissue from one or more devils
from downstream analyses. We further pruned the filtered set of variants by excluding any
variant for which more than 50% samples were assigned the ambiguity code “N.” We addition-
ally removed any tumours where more than 50% variants were assigned the ambiguity code
“N.”
Copy number calling
For autosomes, we counted read depth in adjacent 100-kb genomic bins across Devil7.1+MT,
excluding the last bin of each scaffold as well as short (<100 kb) and unplaced scaffolds. Addi-
tionally, the short scaffolds placed towards the end of each autosome were excluded, as speci-
fied in [18]. For chr X, which is enriched for short scaffolds, we first concatenated scaffolds
prior to bin counting and did not exclude the last bin of each scaffold. Scaffolds beyond posi-
tion chrX:54800000 (S12 Table) were excluded. Bin counts were normalised by log2 trans-
forming the ratio of read depth within each bin to median autosomal read depth in the panel
of normal (PON) genomes (LogR). Normal devil genomes were pooled into a PON and used
to denoise tumours using tangent principal component analysis (PCA) normalisation (https://
gatk.broadinstitute.org/hc/en-us/articles/360037593691-DenoiseReadCounts). LogR plots
(tumours), raw read depth plots (normal devils), and raw read count per bin (tumours and
normal devils) are available in S2–S4 Data in https://doi.org/10.5281/zenodo.4046235,
respectively.
Table 5. Thermal cycling conditions for MIP amplification and index incorporation.
Temperature Time Cycles
98˚C 30 s 1×
98˚C 15 s 23×
58˚C 30 s
72˚C 30 s
72˚C 2 min 1×
https://doi.org/10.1371/journal.pbio.3000926.t005
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Purity calculation
Tumour purity was calculated using copy number features as follows. We estimated purity (ρ)
using average read depth calculated in 10-kb intervals with a 5-kb slide across the genome (rgenome)
and genomic regions that have lost either 1 (rLOH) or both (rHomdel) copies in all DFT1 or DFT2
tumours. These regions were identified by assessing copy number states through nonoverlapping
10-kb windows across targeted scaffolds (Table 6). The following formula was used, where n and k














See S12 Table for equivalence of scaffold names. Purity was also estimated from MIP geno-
types, as described above in section “MIP genotyping.” The mean of both methods was used in
downstream analyses. Purity estimates obtained from both methods are available in S1 Table.
Copy number segmentation. LogR profiles were segmented using both piecewise con-
stant fitting (pcf) and multiple-sample pcf (multipcf), implemented in R [52]. multipcf was
run on groups of tumours with shared mtDNA haplotypes (S1 Table). If pcf and multipcf seg-
ments within a single tumour shared a copy number state (see below) and overlapped across
>95% of their length, they were merged, and multipcf breakpoints retained. The union of pcf
and multipcf segments was further filtered by merging adjacent segments whose read depth
dispersions were not significantly different (p = 0.05) using Ansari–Bradley and Wilcoxon
tests (https://rdrr.io/bioc/aCGH/). Non-copy number 2 (CN2) segments called in different
tumours were merged if they overlapped across >95% of their length and had breakpoints
within 500 kb of each other. In these cases, breakpoints were consolidated to the median posi-
tion of observed breakpoints. Finally, segments <500 kb were discarded. Each tumour’s seg-
ments were visually inspected and validated (S2 Data in https://doi.org/10.5281/zenodo.
4046235). Breakpoints were screened for absence in the set of normal devil genomes (S3 Data
in https://doi.org/10.5281/zenodo.4046235).
Copy number assignment. The copy number associated with each segment was estimated
using two models: a Bayesian hierarchical model implemented in JAGS (http://www.stats.ox.
ac.uk/~nicholls/MScMCMC15/jags_user_manual.pdf) and a Poisson logit-linked general lin-
ear model implemented in R.
Bayesian hierarchical copy number assignment. The read depth of a segment (rs) can be esti-
mated by the sample’s ploidy (ψ) and purity (ρ), defined as the proportion of tumour cells in a
sample, as well as the segment’s copy number state (Eq 1) [53]. We developed a Bayesian hier-
archical model with a Markov chain Monte Carlo-based Gibbs sampler implemented in JAGS
Table 6. Coordinates and deletion class for scaffolds used in purity calculation.
Type Deletion class Scaffold coordinates
DFT1, DFT2 LOH Chr3_supercontig_000000288:1090000- Chr3_supercontig_000000297:40000
DFT1 LOH Chr2_supercontig_000000346:1- Chr2_supercontig_000000353:269000
DFT1 Homdel Chr2_supercontig_000000278:490000–510000
DFT2 LOH Chr1_supercontig_000000015:1- Chr1_supercontig_000000027: 440000
DFT2 LOH Chr5_supercontig_000000095:1- Chr5_supercontig_000000109:650000
DFT2 Homdel Chr3_supercontig_000000242:130000–190000
DFT, devil facial tumour; Homdel, homozygous deletion; LOH, loss of heterozygosity.
https://doi.org/10.1371/journal.pbio.3000926.t006
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(http://www.stats.ox.ac.uk/~nicholls/MScMCMC15/jags_user_manual.pdf) to fit the read
depths of segments in each tumour and to obtain estimates of a tumour’s purity and ploidy
and calculate copy number states. For DFT1 tumours, we estimated purity through DFT1-spe-
cific regions of deletions in the genome and MIPs data (see above). We used the average of
these tumour purity measurements to initialise the tumour purity parameter of the model.
Rearranging the formula in Eq 1, we then used the optimised tumour purity and ploidy esti-
mates and the read depths of the segments to assign copy number to the segments (Eq 2).
rs ¼ log2





ðc2rs   2ð1   rÞÞ
r
ð2Þ
Poisson model for copy number assignment. As a cross-validation measure, we obtained the
idealised logR for copy number states 1 to 9 using the tumour purity and ploidy estimates
using Eq 1 and generated a Poisson mixture model implemented in R to compute the probabil-
ity that given its read depth, a segment will be of a particular copy number state. The base
assumption in this model is that copy number state (n) scales linearly with read coverage (k)
(Eq 3). To calculate expected read coverage states for this model, we first calculated the average
read coverage of the segments that were assigned as CN2 by the previous copy number assign-
ment model (k̃). We then inferred the expected read coverage of the other copy number states,
multiplying the predicted read coverage by the tumour purity (ρ) to account for host contami-
nation. We assume that the read coverage distribution within copy number states is under a
log-gamma distribution. Using the Poisson mixture model, we then assigned each segment to





PðnÞ ¼ eðk logðrnÞ  rn   lgammaðkþ1ÞÞ ð4Þ
Discrepancies between copy number assignments using the two methods due to low
sequencing quality and subclonality were manually validated based on raw read coverage. To
further remove false positive breakpoints, adjacent segments that were assigned the same copy
number state were merged. Copy number states in all tumours were visually inspected and val-
idated (S2 Data in https://doi.org/10.5281/zenodo.4046235) and mtDNA and MIP phyloge-
netic trees were used to identify and split recurrent CNVs and to infer back mutations.
Whole genome duplication was inferred using karyotype information (S1 Table), together
with observations of CNV copy number states.
Phylogenetic tree
The phylogenetic tree of DFT1 tumours was inferred jointly from three sources of sequence
data: SNVs of the nuclear genome derived from MIP sequencing, mtDNA SNVs and binary
presence-absence information corresponding to the CNVs observed in each sample. CNVs
associated with M5 and high copy number amplicons were excluded from tree inference. The
data were analysed using IQ-TREE 1.6.12 [54], under an edge-linked proportional partition
model (-spp option) [55], in which each of the three data sources formed a subset of the parti-
tion, to which was assigned its own substitution model. The substitution model for each subset
was chosen using IQ-TREE’s model selection procedure (-m MF option) [56], with the
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following results: MIP SNVs were analysed using K2P+ASC+R2, mtDNA SNVs were analysed
using TIM2e+ASC, and CNVs were analysed using GTR2+FO+ASC+R3. Branch support was
assessed using IQ-TREE’s ultra-fast bootstrap [57] with 1,000 replicates (-bb 1,000 option).
The devil reference sequence (Devil7.1+MT) was used as an out-group to root the tree.
Two tree search strategies were employed in the phylogenetic analysis: one in which all can-
didate trees must conform to a topological constraint (using the -g option of IQ-TREE) [58]
and an unconstrained tree search. The topology constraint used was to enforce the samples’
preassigned membership to clades A1, A2, B, C, D, and E, based on mtDNA haplotypes and
presence of clade-specific SNVs from low coverage whole genome sequencing data (this was
relevant for samples missing MIPs data (S1 Table)), as well as to group samples 332T and
471T1, which share an mtDNA haplotype, but 471T1 is missing MIPs data. We ran 20 inde-
pendent runs for each strategy. We used the approximately unbiased (AU) test [59] to identify
any trees that were statistically significantly worse than the maximum likelihood tree among
the set. The highest likelihood constrained tree not rejected by the AU test is presented in Figs
1 and 3 and S1 Fig.
Clade group assignment
We assigned tumours to 37 “clade groups” (S1 Table and S1 Fig) based on position in a phylo-
genetic tree constructed from MIP and mtDNA genotypes. These were designated with a
numeric suffix after specifying the clade (A1, A2, B, and C), e.g., Clade_A1-1, Clade_A1-2, etc.
One clade B cell line, 204T, lacked MIPs data and could not be confidently placed within a
group; it was therefore assigned its own group, Clade_B-204T. Clade groups and phylogenetic
position within the MIPs+mtDNA tree were used to identify CNV recurrence and back
mutation.
CNV rate and genome size variation rate
The accumulation of CNVs with time was plotted using the R package ggplot2. Data were ana-
lysed using a linear model; concretely, the lm() function and prediction intervals were inferred
by the predict() function implemented in the R programming language. Models were inferred
for the relationship between the number of CNVs and the sampling date and for the number
of CNVs and the interaction between the sampling date and the DFT1 clade. The significance
of the interaction with clade was assessed using analysis of variance (ANOVA), through the
Anova() function in the R package “car,” and contrasts between pairs of clades were assessed
using the emtrends() function in the R package estimated marginal means (“emmeans”). Sets
of CNVs which cooccur with the same copy number in the same samples are counted once
(see Total_CNVs_linked.clonal_copynumbers_only in S1 Table). We corrected for ploidy in
tetraploid tumours (CNVs occurring after whole genome duplication were counted as half a
CNV, as there is twice as much DNA in which CNVs can occur after this event). Exact sam-
pling dates were unavailable for 23 samples, although the year of sampling was recorded; for
these samples, a random date from the year of sampling was used when calculating the
regression.
Diploid DFT1 genome size rate of change with time was analysed as follows. Genome size
change was calculated for each tumour by subtracting the “total genome affected loss” from
the “total genome affected gain” where “total genome affected gain” and “total genome affected
loss” are the sum of the widths of the copy number gain and copy number loss CNVs present
in each sample, respectively (S1 Table). Genome size per sample is calculated as 2�haploid
genome size + genome size change, where callable haploid genome size was estimated as
2,625,758,988 bp (this excluded regions of the genome which were excluded from copy
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number analysis, see above). The rate of change of diploid DFT1 genome size due to copy
number variation over time was estimated by robust regression, implemented in the R package
MASS, in the function rlm. The “Genome size” response was regressed on the sampling date
for each sample. Non-DFT1s, duplicate samples from the same tumour, cell lines, and tetra-
ploid tumours were excluded from this analysis, as were CNVs with subclonal copy number
states. Exact sampling dates were unavailable for 23 samples, although the year of sampling
was recorded; for these samples, a random date from the year of sampling was used when cal-
culating the regression.
Allelic copy number
We estimated allelic copy number by intersecting CNV and MIP coordinates. CNV–MIP com-
binations were only retained if the MIP alternative allele was either present in the tumour(s)
carrying the CNV (gains) or inferred to be present in an ancestor tumour (losses). CNV–MIP
combinations were further filtered for those that overlapped with 2 or more independent CNVs
to assess whether specific alleles are involved in recurrent CNVs.
Each MIP position has an associated estimated total copy number and an observed VAF,
and each sample has an estimated purity; these values are used to estimate the genotype. For a
given total copy number, we construct an array of potential genotypes, in half-integer intervals,
to test. For example, for a total copy number of 2, we would test the genotypes 0.0|2.0, 0.5|1.5,
1.0|1.0, 1.5|0.5, and 2.0|0.0, where the genotype is written in the format “R|A,” with R meaning
“reference allele” and A meaning “alternative allele.” We calculate the expected VAF for each
genotype as
VAF ¼
HAltð1   pÞ þ TAltp
HTotalð1   pÞ þ TTotalp
;
where H and T represent the copy number in the host and tumour, respectively, and the sub-
scripts Ref, Alt, and Total designate that the copy number refers to the reference or alternative
allele or is the total copy number, and p is the sample purity. For the MIP positions under con-
sideration, HAlt = 0 and HRef = 2. The genotype which minimised the absolute difference
between expected and observed VAF was selected as the best fit allele-specific copy number
genotype at the MIP position for the sample (S11 Table).
To further validate the finding that any copy of chromosome 4 can be lost in the back muta-
tions of CNVs 3R1 and 9 commonly observed in DFT1 cell lines, we performed capillary
sequencing of four variant loci occurring within the footprints of CNVs 3R1 and 9 (S11
Table). All four SNVs were inferred to be present in the DFT1 most recent common ancestor.
The following primers were used to amplify these loci as approximately 400 bp amplicons in
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PCRs were performed in 40-μl reactions with the following reagents: 8-μl 5× Phusion HF
Reaction Buffer (New England Biolabs), 4-μl DNA template, 0.8-μM dNTP mix (New England
Biolabs), 0.8-μM forward primer, 0.8-μM reverse primer, and 2.5-U Phusion HF DNA Poly-
merase (New England Biolabs). Thermal cycling was performed as follows: 3:30 minutes at
94˚C, then 30 cycles of 30 seconds at 94˚C, 30 seconds at 60˚C, 30 seconds at 72˚C, followed
by 5 minutes at 72˚C using an Eppendorf thermal cycler (Eppendorf, Hamburg, Germany).
Genotypes were called manually by viewing electropherograms using Geneious R9 software
(Biomatters, Auckland, New Zealand).
Simulated CNV distributions
We assessed whether the observed overlap of independent CNVs was statistically greater or
less than expected by chance. We sampled random regions from the genome that matched the
sizes of the observed CNVs identified in DFT1s and assessed their overlaps. We performed
2,000 permutations to simulate the null hypothesis that the occurrence of observed CNVs in
our set was not associated with genomic position. For the simulation, the genome was circular-
ised in numerical order such that the end of a chromosome is connected to the start of the
next, higher number chromosome; the end of chromosome X is linked to the start of chromo-
some 1. For each observed CNV, the start position was randomly resampled from all available
genome positions, and the end position of the CNV was updated to a position downstream of
the new start position such that the original CNV length was maintained.
Visualisation of clade spread
We used a customised R script using the R package “ggplot2” to overlay a plot of the coordi-
nates of each sample to a map of Tasmania (https://library.unimelb.edu.au/collections/map_
collection/map_collection_outline_maps) to assess the spread of each identified clade.
Telomere repeat abundance analysis
Telomere repeat abundance was estimated from binary sequencing alignment map (BAM)
files using a modified version of telseq version 0.0.1 [60], using merged read groups and a read
length of 125, appropriate for the sequencing technology used (-m -r 125 option). We modified
parameters in the telseq source code to adapt it for the devil genome, which include read
length, total GC content (bp), and number of chromosomal ends. The number of chromo-
somal ends was specified as 1 in order to obtain a measure of overall telomere repeat abun-
dance rather than an estimate of telomere length. The modified source code is available at
https://github.com/TransmissibleCancerGroup/telseq.
The relationship between the estimated telomere length and the year of sampling was esti-
mated using a generalised linear model, using a log-linked gamma distribution to model errors
and to reflect that the length estimates can only take positive values. The implementation used
was the glm() function in the R programming language. “Telomere length” estimated by telseq
is the cumulative length of telomere repeats and will include interstitial telomere repeats.
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DFT1 face maps
DFT1 tumour images from confirmed DFT1s (S1 Table) were used to construct DFT1 face
and body maps. Facial and body tumour contours from photographs or field notes were hand
drawn onto devil face and body templates using Krita software (Krita, Deventer, the Nether-
lands) on a Wacom Intuos Pro tablet (Kazo, Japan). We generated a custom python script
using “matplotlib” and “opencv” packages to stack the tumour contour diagrams and to quan-
tify the density of tumour occurrence across the devil face and body (Fig 1F and S1 Data in
https://doi.org/10.5281/zenodo.4046235).
Computer code
Custom software and code associated with this study are available in the repository (https://
github.com/TransmissibleCancerGroup/TCG_2020_devil_paper).
Supporting information
S1 Fig. DFT1 phylogenetic tree. Phylogenetic tree of 639 DFT1 tumours, including cell lines,
constructed with 456 MIP genotypes, 94 mtDNA mutations, and 932 CNVs; this is a higher
resolution version of the tree shown in Fig 1A. Each tumour is labelled with its ID, location
and year of sampling, and clade group (S1 Table). Nine tumours (8T2, 9T, 120T, 166T4,
390T1, 460T1, 478T2, 1070T1, and 1072T1) were excluded due to substantial missing data;
these tumours’ clade groups can be found in S1 Table. The 26 tumours labelled in italic font
have missing data or very low purity, and their exact positions on the tree may be inaccurate;
in these cases, likely true phylogenetic position is presented with the labelled clade group and
in S1 Table. Bootstrap values from 1,000 replicates are reported for each node. Some nodes
(base of clades A, B, C, and D and that linking samples 332T and 471T1) were constrained,
and as a result, bootstrap values are shown as 100. Branch lengths are proportional to number
of mutational events, not evolutionary time. Sample information is available in S1 Table, and
SNV and CNV genotypes are available in S2 and S3 Tables, respectively.
(PDF)
S2 Fig. DFT1 sample locations by year. Locations of 593 DFT1 tumours collected between
2003 and 2018, coloured by clade. These are the same data as shown in Fig 2B, but split by
year. Map outline was obtained from https://library.unimelb.edu.au/collections/map_
collection/map_collection_outline_maps. Underlying data are available in S1 Table.
(PDF)
S3 Fig. DFT1 tumour body locations. Locations of confirmed DFT1 tumours illustrated on
Tasmanian devil (A) face, right-hand side, (B) face, left hand side, and (C) body diagrams.
Scale represents number of tumours. The number of individuals in the sample with tumours
within the relevant body area were 36, 32, and 32, top to bottom. Underlying data are available
in S1 Data in https://doi.org/10.5281/zenodo.4046235.
(PDF)
S4 Fig. DFT1 tetraploid lineages. Clade and temporal distributions of the eight observed
DFT1 biopsy tetraploid lineages. The years of first and most recent observations of each line-
age are indicated. Each lineage is labelled with a numeric ID. Lineage 8 was observed only in a
cell line and is not included. Data are available in S1 Table.
(PDF)
S5 Fig. CNV rates by clade. Rate of CNV acquisition in DFT1 clades. X-axis represents collec-
tion date, with labels representing 1 January of the labelled year. Sets of CNVs which cooccur
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with the same copy number in the same samples are counted once, and we corrected for ploidy
in tetraploid tumours. DFT1 cell lines were excluded. The difference in rate between clade C
and the other clades is statistically significant (p< 0.005, pairwise contrasts of emmeans, with
Tukey multiple testing adjustment). Coloured shading represents regression standard error,
and upper and lower lines represent prediction intervals. Data are available in S1 Table
(Total_CNVs_linked.clonal_copynumbers_only) and S3 Table.
(PDF)
S6 Fig. DFT1 diploid genome size variation with time. Diploid genome size was estimated
for each tumour by adding and subtracting CNV gain and loss footprints from the diploid Tas-
manian devil callable genome size (haploid size, 2,625,758,988 bp). X-axis represents collection
date, with labels representing 1 January of the labelled year. Subclonal CNVs, tetraploid
tumours, duplicate tumours, and cell lines were excluded. Each tumour is represented by a
dot, and shading represents regression standard error. Robust regression was performed, p-
value for association = 0.3849 (robust F-test). Data are available in S1 and S3 Tables.
(PDF)
S7 Fig. CNV burden in DFT1 primary tumours and metastases. Number of CNVs does not
differ between DFT1 biopsies collected from primary facial tumours (n = 543) and internal
metastases (n = 24). Each dot represents a tumour. Data are available in S1 Table.
(PDF)
S8 Fig. Clade-specific CNV maps. Chromosome map illustrating subsets of CNVs in DFT1
biopsies (A) shared by all DFT1s; (B) exclusive to and shared by all DFT1s in clades A, B, C,
and D; (C) exclusive to clade E; (D) exclusive to clade A1; (E) exclusive to clade A2; (F) exclu-
sive to clade B; (G) exclusive to clade C; (H) exclusive to clade D. Grey bars represent chromo-
somes, with scale on left in bp. Blue and red bars represent copy number losses and gains,
respectively. Each bar is an independent CNV occurrence, and CNVs shared by multiple
tumours via a common ancestor are illustrated once. Each CNV step away from CN2 is illus-
trated separately, thus a CNV present at CN <1 or>3 is shown multiple times. Data are avail-
able in S3 Table.
(PDF)
S9 Fig. Maps for intersecting CNVs between devil cancers. Chromosome map illustrating
recurrent CNVs with identical breakpoints (at 100-kb resolution) occurring within one or
more tumours belonging to each cancer group in each of the subsets: (A) DFT1 and DFT2; (B)
DFT1 and non-DFTD; and (C) DFT2 and non-DFTD. Non-DFTD, non-devil facial tumour
disease, i.e., neither DFT1 nor DFT2. Grey bars represent chromosomes, and gains and losses
are represented by coloured bars above and below the chromosomes, respectively. The colour
key identifies the tumours whose CNVs are represented by each colour. Three non-DFTD
tumours (106T1, 106T2, and 106T3) belong to the same non-DFTD cancer sampled from 3
body sites and CNVs were collapsed (106Tx). No CNVs occurring independently in more
than one non-DFTD tumour, or in one or more DFT1, DFT2 and non-DFTD tumour were
found. This figure refers to recurrent CNVs between devil cancers, and differs from Fig 2I,
which describes reused single breakpoints. Underlying data are available in S3 Table.
(PDF)
S10 Fig. Allelic copy number. CNV chromosome map displaying CNVs from DFT1 biopsies
and cell lines whose footprint encompassed genotyped MIP alleles (S2 Table and S3 Table).
MIP genotypes and CNVs are only shown if the CNV depth in a single direction (gain, loss)
was�2 and if the MIP ALT allele was either present in the tumour(s) carrying the CNV
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(gains) or inferred to be present in an ancestor tumour (losses). Gains are coloured red and
losses blue, and chromosome coordinates in bp are shown in scale bar on left. The allele (REF,
ALT) implicated in each CNV is shown and CNV IDs (S3 Table) are labelled. CNVs 3R1 and
9, parental CNVs of the recurrent chromosome 4 back mutations observed in cell lines, are
shown three times each in order to illustrate informative MIPs genotypes that were captured
in different samples. The figure shows only directly observed genotypes, although in some
cases additional genotypes can be imputed. Lines connect CNVs that cooccur on the same
chromosome in the same direction (gain, loss) in the same tumour(s) and which may be
linked. None of the stacked genotyped CNVs reached the minimum threshold (9) needed to
obtain sufficient power to detect allelic skew with a Fisher exact test. Data are available in S11
Table.
(PDF)
S11 Fig. DFT1 biopsies with similar CNV profiles to cell lines. Genomic copy number plots
for two DFT1 tumours, a lung metastasis (134T6 and a tumour biopsy of unknown body loca-
tion (likely facial) (428T1)), with CNV profiles similar to those seen in DFT1 cell lines. The
changes observed in 428T1 occurred after whole genome duplication. Copy number plots
from the primary facial tumour from the same animal as the lung metastasis (134T1), and a
representative cell line (214T), are also displayed. Each dot represents normalised read cover-
age within a 100-kb genomic window. R, ratio of tumour to normal reads, log base 2. Tumour
identifiers are labelled in parentheses. Copy number plots for all tumours are available in S2
Data in https://doi.org/10.5281/zenodo.4046235.
(PDF)
S12 Fig. DFT1 telomeres. (A) Telomeric repeat length in DFT1, DFT2, and normal devils
(“hosts”). Each sample is represented by a dot. Five outliers in the “host” group are not shown
on the plot but were included in the data used to generate boxplot. Data are available in S1
Table. (B) Linear regression of telomere repeat length and year of collection for DFT1 biopsies
with tumour purity included as a covariate. Residual errors are plotted in red, and blue shading
represents the standard error of the gradient estimate. In both (A) and (B), telomere length is
the cumulative length of telomere repeat (TTAGGG) detected in the genome, including both
telomeric and interstitial repeats, which cannot be distinguished using this method.
(PDF)
S1 Table. Sample information. (A) Tumour sample information. Identifiers and metadata are
listed for DFT1, DFT2, and non-DFTD tumours (non-DFTD refers to tumours which are nei-
ther DFT1 nor DFT2). Each row refers to a single tumour, with multiple samples from the
same individual devil linked by a common individual ID and a digit following the “T,” e.g.,
31T1 and 31T2 are two tumours sampled from the same host. Further information on devils
with multiple tumours can be found in S4 Table. In some cases, “T1” and “T2” refer to the
same tumour sampled twice, either at the same or different time points; these are labelled as
“duplicate DNA extraction from the same tumour” (same time point) or “Time-course” (dif-
ferent time points). Cell line samples are also labelled “T,” and samples from the same cell line
collected at the same or at different passages are labelled “T1” and “T2,” with those collected at
the same time point labelled “Duplicate cell pellet.” In addition, the following group of cell
lines and experimental transmissions all derive from the same parental cell line (87T, 87T2,
90T, 90T2, 114T, 363T1, 993T1.1, 993T1.2, 994T1.1, 995T1.1, 995T1.2, 996T1, 996T2). Cell
lines used in the study are also known by the following external identifiers: 85T (Half-Pea);
86T, 86T2 (1426); 87T, 87T2, 90T, 90T2, 114T, 363T1, 993T1.1, 993T1.2, 994T1.1, 995T1.1,
995T1.2, 996T1, 996T2 (C5065); 88T, 88T2 (4906); 204T (Ed); 202T2 (RV, TD467); 203T3
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(SN, TD500). “Matched” and “unmatched” refer to availability of host (see (B)). Clade and
clade group (S1 Fig) are listed for each tumour, as well as mitochondrial haplotype group and
genotype (S1 Fig and S2 Table). Tumour purity estimates from copy number analysis, MIP
genotyping, and mitochondrial analysis are shown. Tumour data, including sampling location,
latitude, longitude, date of sampling, host age, and sex (M, male; F, female), are provided. “Sin-
gleton” and “multiple” denote individuals from which either a single tumour or multiple
tumours were sampled as part of the set, and information on tumour body location is pro-
vided, when known. Tumours sampled from an internal body location are marked “metasta-
sis.” Information on the diagnosis of non-DFTD tumours is provided. Cell lines and tumour
biopsies derived from experimental transmission trials involving either cell lines or tissue biop-
sies are marked [26], with inoculation date provided, if known. Tumour strain refers to cyto-
genetic analysis [13]. Subsets of samples included in the phylogenetic tree (Fig 1A and S1 Fig)
and in geographical analyses (Fig 1B–1D and S2 Fig) are indicated, including those that are
italicised in S1 Fig. Subsets of samples for which different data types are available (mtDNA
haplotype, CNVs, and MIPs genotypes) are listed. Samples which are duplicate biopsies sam-
pled from the same tumour at the same time, duplicate cell pellets from a single cell culture, or
which are samples from the same tumour or cell line collected on different dates (time course)
are indicated. M5 genotype is provided, with blank indicating that M5 is retained. Tetraploid
tumours are marked, and the tetraploid lineage to which each tetraploid tumour belongs is
listed in parentheses (S4 Fig). CNV burdens and the width of genome affected (bp) are pre-
sented, with separate data for all CNVs and clonal CNVs only. CNV strings are concatenated
lists of CNV IDs (S3 Table) and “linked CNVs” groups together those CNVs that cooccur in
the same direction (gain, loss) in the same samples and which may have occurred as a single
event (S3 Table); CNVs present in a sample that do not form part of a linkage group are
included in this count as singleton groups. Fig 2C and S5 Fig show data for “linked CNVs,”
with CNVs occurring after whole genome duplication counted as half a CNV in order to cor-
rect for genome size. Subclonal CNVs could not be called in tetraploid tumours and the “clonal
only” fields have been left blank in these tumours. Telomere length data, presented in S12 Fig,
are available in column labelled “Telseq_Length_Estimate.” “SangerStudyIDs” contains addi-
tional sample identifiers. (B) Normal devil sample information. Sample ID, microchip (if
known), trapping location, gender, and year of sampling are indicated. If the individual is a
matched host from a tumour in the study it is marked “matched,” otherwise, it is labelled
“unmatched.” Availability of WGS and MIP data are marked. Telomere length data, presented
in S12 Fig, are available in column labelled “Telseq_Length_Estimate.” “SangerStudyIDs” con-
tains additional sample identifiers.
(XLSX)
S2 Table. MIP and mitochondrial genotypes. (A) MIP genotype expressed as VAF. The num-
ber of reads supporting the variant and the number of reads covering the variant site are
shown for each MIP–tumour combination. MIP probe sequences are shown, “N” within the
MIP probe sequence denotes the 5-bp UMI. (B) Tumour genotypes across the MIP panel. N,
genotypes that could not be determined. MIP probe sequences are shown, “N” within the MIP
probe sequence denotes the 5-bp UMI. (C) Contaminating read threshold, determined empiri-
cally for each tumour, used in genotype calling (see Methods). (D) Mitochondrial (mtDNA)
genotypes. Numerals “1” and “0” represent variant presence and absence, respectively. (E)
mtDNA haplotype nomenclature. DFT1 mtDNAs are arranged into 36 haplotype groups,
based on the presence of haplogroup-defining variants. Haplotypes falling within defined
groups acquiring additional variants are named hierarchically with letters and numbers, as
shown. Haplogroups DFT1_18 and DFT1_30, as well as haplogroups DFT1_22 and DFT1_29,
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are each defined by the same variant (10620T>A and 16143G>A, respectively). The single
DFT2 haplotype is also listed. DFT1_0 and DFT2_0 are identical to the reference genome.
Small insertions and deletions (indels) are not included.
(XLSX)
S3 Table. Copy number variants. The table has one row per CNV, with coordinates, width
and type (gain, loss) shown. Each CNV is assigned a basic ID and an extended ID. The basic
numeric ID is unique to the pair of coordinates and type (gain, loss), regardless of phylogenetic
relationship and may be present in multiple rows (with the exception of partial back muta-
tions, which share the same CNV ID as the parent CNV, but whose coordinates are within the
parent CNV footprint). The extended ID is unique per row and incorporates additional infor-
mation with the following suffixes: R (recurrence, a repeated phylogenetically unrelated CNV
involving the same coordinates and type; each recurrence is numbered), BM (back mutation, a
CNV which returns a phylogenetically earlier CNV to CN2 or another lower amplitude state),
PBM (partial back mutation, similar to BM, but the CNV coordinates lie within the parent
CNV footprint), G (gain, higher amplitude gain beyond CN3; each independent gain is
labelled, i.e., G1, G2, etc., and the copy number state is also labelled, i.e., G1CN4), and L (simi-
lar to G, but for losses below CN1). The samples and clade groups of samples carrying each
CNV are listed in the “Sample_group” column, together with the copy number state assigned.
Subclonal copy number states are expressed as a 0.5 step between the two closest integer states.
“Copy_number” lists each state found in samples carrying the CNV, and the number of sam-
ples with copy number at each state are shown. In cases where back mutations have occurred,
final copy number state is presented also in the parent CNV, including in cases where the back
mutation is partial. CNVs that occur uniquely in cell lines or in cell lines experimentally inocu-
lated into animals are tagged, and “Cancer_type” specifies if the CNV occurs in DFT1, DFT2,
or non-DFTD tumours. The “subclonal” tag marks CNVs that have non-integer copy number;
however, these may also include integer copy number states in tetraploid tumours (tagged).
CNVs that occur exclusively within tetraploid tumours are marked, together with the whole
genome duplication (WGD) event number in parentheses (S4 Fig); CNVs that are inferred to
have occurred in a common ancestor of a tetraploid tumour group prior to WGD are marked;
others are inferred to have occurred after WGD. Linkage groups tag groups of CNVs that
cooccur in the same direction (gain, loss), and CNVs that involve the same coordinates but the
opposite direction (gain, loss) are marked. Nested CNVs are CNVs that have arisen within the
coordinates of a “parent” CNV and are in the same direction (gain, loss) as the parent. The
total number of tumours carrying each CNV is listed in the “Number_of_tumours” column.
CNVs that were part of the M5 complex or which were part of high-level amplicons were not
used to generate the phylogenetic tree (Fig 1 and S1 Fig) and are tagged in the “Do_not_use_-
to_build_tree” column. We have tagged intervals that include physically map markers (labelled
“Deakin_2012_markers” and “Taylor_2017_markers”) [17,31]. The number of tumours carry-
ing each CNV as a fraction of the total number of tumours within each clade group is shown,
as well as individual genotypes for all tumours in the set (“1,” presence; “0,” absence). Copy
number plots labelled with CNV IDs can be found in S2 Data in https://doi.org/10.5281/
zenodo.4046235.
(XLSX)
S4 Table. Tumour genotypes in devils with multiple tumours. Only DFT1 tumours were
considered in this analysis, and DFT1–DFT2 coinfection, which occurred in two devils (Devil-
812 and Devil-818) in the cohort, is not included. (A) Summary of tumour genotype informa-
tion for devils hosting more than one sampled tumour. Each animal has an individual ID, and
individual tumours sampled from the devil are labelled “T1,” “T2,” etc. “Type” lists various
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categories of multiple tumour sampling regimens: “multiple tumours,” when several tumours
were sampled from an individual devil at a single sampling time and “time-course,” when the
same tumour was sampled more than once on different dates. Individuals from which internal
metastases were sampled are tagged “metastases collected,” and the tissue location of the rele-
vant tumour(s) is tagged. Each animal is marked as “same” or “different,” depending on if its
tumour genotypes are distinguishable using the range of markers that we have assessed
(mtDNA and CNVs). Those animals that have different genotypes between multiple tumours
are further classified as “polymorphic public,” i.e., all genotypes identified in the animal are
shared with tumours in other devils, and “polymorphic private,” i.e., any new variation in the
devil’s tumours is found only in that devil. The genetic distance between different tumours
within a single host with polymorphic public genotypes are listed and can include coinfection
with tumours of different clades, different clade groups, or the same clade group. Each geno-
type within a devil is given a number, and these are listed in the “pattern” column. Additional
metadata, as described in S1 Table, are also provided. (B) Genotype information from cell lines
sampled multiple times at different passage or after inoculation into animals. Data are orga-
nised as in (A). (C) Summary of data in parts (A) and (B), with underlying data for Fig 1E.
(XLSX)
S5 Table. Shared subclones. (A) Details of subclonal CNVs identified in two or more DFT1
biopsies. Subclonal CNVs that were identified in a single tumour are not included; CNVs that
were subclonal in some tumours but clonal in others are included. Upper table, CNVs exclud-
ing M5; lower table, M5 subclonality. Linkage group refers to a set of CNVs that cooccur with
the same copy number in the same sets of samples and which likely occurred as a single event,
with numbers referring to CNV IDs (S3 Table). (B) Details of subclonal CNVs identified in
two or more DFT1 cell lines or biopsies from tumours derived from cell lines experimentally
inoculated into animals. Table structure as in (A).
(XLSX)
S6 Table. Gene annotation. Genes wholly or partially present within genomic intervals cov-
ered by CNVs to a specified depth within different subsets of tumours. Interval coordinates are
presented, and “Depth” represents the cumulative coverage across the interval in CNV gains
or losses (specified in “Type”). The CNV IDs of associated CNVs are shown (S3 Table). The
“COSMIC” and “COSMIC summary” columns annotate genes within intervals that are
included in the COSMIC Cancer Gene Census [61] (accessed 18 November 2019), as well as
COSMIC annotation for these genes. (A) DFT1 biopsies (DFT1 cell lines excluded), genomic
intervals covered by at least 3 gain CNVs or at least 3 loss CNVs. HMGA2 is not annotated in
the reference genome Devil7.1, but its presence is inferred in interval 5:17100000–18299999 is
based on alignment with other species’ genomes. (B) DFT1 cell lines, genomic intervals cov-
ered by at least 3 gain CNVs or at least 3 loss CNVs. (C) DFT2, genomic intervals covered by
at least 2 gain CNVs or at least 2 loss CNVs. (D) Non-DFTD tumours, genomic intervals cov-
ered by at least 2 gain CNVs or at least 2 loss CNVs.
(XLSX)
S7 Table. Geographical locations of tumours with PDGFRB copy number gains. CNV IDs
(see S3 Table) and associated copy number states for gain CNVs encompassing the PDGFRB
locus. Tumour identifiers, clades and clade groups, and copy number state within each tumour
are shown. The number of tumours carrying each CNV and the locations and years in which
these tumours were sampled are listed. CNV127 was sampled in 5 tumours, 4 located in Frey-
cinet and 1 located in Bicheno, approximately 10 kilometres from Freycinet.
(XLSX)
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S8 Table. M5 loss. (A) Summary of 27 M5 loss events and two M5 gain events in DFT1 biop-
sies. The M5 loss ID, together with tumour ID, clade group, and information about whether
the sample is a cell line, a duplicate, or tetraploid (together with the tetraploid ID, S1 Table),
are shown. M5 losses observed in cell lines within this set are inferred to have occurred prior
to cell line establishment. M5 loss is defined as having CNVs 6BM (chromosome 2) and 11BM
(chromosome 5) and at least one of the chromosome X events, 16R, 17R, 18R. CNV IDs for
each event are provided (see S3 Table). Samples in which M5 loss is subclonal are tagged. In tet-
raploid tumours with polymorphic loss of both M5 copies within the tetraploid group, two M5
loss events are inferred. (B) Summary of 13 M5 loss events occurring exclusively in cell lines in
culture or cell lines after inoculation into animals and interpreted as having occurred after cell
line establishment. Tumour ID, clade group, and subclonality are indicated, as well as CNV
IDs. (C) Observed and expected M5 losses and M5 losses per diploid genome in DFT1 biopsies,
cell lines, diploid biopsies, and tetraploid biopsies. Only DFT1s with CNV data are included in
the total counts, and duplicates are excluded. “M5 loss ID” refers to parts (A) or (B).
(XLSX)
S9 Table. Breakpoint reuse. Coordinates of CNV breakpoints, excluding starts and ends of
chromosomes and breakpoints associated with M5. CNV IDs (see S3 Table) associated with
the breakpoints and counts of breakpoint use in DFT1, DFT2, and non-DFTD tumours are
shown. Three non-DFTD tumours (106T1, 106T2, and 106T3) belong to the same non-DFTD
cancer sampled from 3 body sites and breakpoints are collapsed. “Breakpoint” refers to a single
coordinate in the genome that was observed to be involved in either a gain or loss CNV. This
is different to the data shown in S9 Fig, which shows recurrent cross-cancer CNVs with identi-
cal pairs of reused breakpoints.
(XLSX)
S10 Table. DFT1 cell line CNVs. Summary of recurrent CNVs associated with DFT1 cell
lines. The recurrent CNVs commonly observed in DFT1 cell lines fall into two linked clusters,
involving losses on chromosomes 1, 2, and 4 and gains on chromosomes 5 and X, respectively.
IDs and coordinates of CNVs part of each cluster are shown, together with genotypes in cell
lines and in 18 DFT1 biopsies, which have acquired one or more of the common cell line
CNVs. Each independent event, which may be shared between multiple tumours via a com-
mon ancestor, has either a “cell line event” or “biopsy event” ID. The tumours associated with
each event are listed, together with clade group and metastasis/primary identity if relevant.
Tetraploid tumours, together with tetraploid lineage in parentheses, are marked. CNV IDs for
each event are shown (see S3 Table). Clonal changes in tetraploid tumours are denoted as sub-
clonal. SC, subclonal; PBM, partial back mutation.
(XLSX)
S11 Table. Allelic copy number. (A) Summary of CNVs from DFT1 biopsies and cell lines
whose footprint encompassed genotyped MIP alleles (S2 and S3 Tables), as presented in S10
Fig. MIP genotypes and CNVs are only listed in table if the CNV depth in a single direction
(gain, loss) was�2 and if the MIP ALT allele was either present in the tumour(s) carrying the
CNV (gains) or inferred to be present in an ancestor tumour (losses). Details of the sample
(clade group, purity), CNV (CNV ID, coordiantes, type (gain, loss), copy number state) and
MIP (MIP ID, coordinate, REF and ALT alleles, VAF within the indicated sample) are pro-
vided. The best fit genotype (in increments of 0.5) and allele implicated in the CNV are shown.
CNVs 3R1 and 9, the parental CNVs of the recurrent chromosome 4 back mutations observed
in cell lines, are shown three times each in order to illustrate informative genotyped loci that
were captured in different samples. (B) Genotypes at four informative loci in 16 DFT1s (15 cell
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lines, 1 biopsy) within the chromosome 4 region repeatedly lost in cell lines (CNV IDs 3R1
and 9). The cell lines have CN2, whereas the biopsy, similar to the DFT1 MRCA, has CN3 at
these loci. The 3 chromosomal copies (designated chromosomes A, A1, and B, where A and
A1 are somatic duplicates) present in the DFT1 MRCA are shown, and the chromosome
inferred to have been lost by each cell line is indicated. The clade group to which each cell line
belongs is shown. Samples 87T2 and 90T are a single cell line collected at different passages
sequenced independently with identical results. “N,” genotype undetermined.
(XLSX)
S12 Table. Genome coordinates. Equivalence between genome coordinates used in this study
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